NCT06866548进行中（未招募）1 期
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Safety and adverse event incidence rate
研究概览
简要总结
This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.
详细描述
This trial is designed to primarily confirm the safety and tolerability of anti-IGF-1R mAb (Teprotumumab/IBI311) in combination with anti-PD-1 mAb (Tislelizumab) using the recommended dose level for patients with mCRPC patients. Additionally，this trial is aimed to evaluate the clinical efficacy of anti-IGF-1R mAb combined with anti-PD-1 mAb in the treatment of mCRPC patients and to investigate whether the combined treatment can enhance endocrine therapy sensitivity in mCRPC patients. As for exploratory objectives，the trial is designed to identify and validate predictive biomarkers associated with therapeutic efficacy and safety profiles of the combination regimen in mCRPC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men over 18 years old and under 85 years old;
- •Diagnosed with prostate adenocarcinoma by prostate biopsy pathology report;
- •Patients with metastatic castration-resistant prostate adenocarcinoma (mCRPC);
- •evidence of metastatic bone lesions on imaging such as PSMA-PET-CT or bone metastasis imaging ECT;
- •Serum testosterone in the depot range (< 50 ng/dL or 1.75 nmol/L);
- •Patients need to be willing to undergo pre- and on-treatment biopsy;
- •ECOG score ≤ 2;
- •Expected survival time of 6 months or more;
- •Substantially normal bone marrow, liver and kidney function:
- •white blood cell (WBC) > 3 x 10^9 cells/L
- •Absolute neutrophil count (ANC) > 1×10^9 cells/L
- •Hemoglobin >9.0 g/dL
- •Platelet count >100×10^9/L
- •Serum creatinine <1.5 × upper limit of normal (ULN)
- •Serum total bilirubin <1.5 × ULN
- •Serum glutamine aminotransferase <3 × ULN
- •Aspartate aminotransferase <3 × ULN
- •willingness to cooperate and complete study follow-up and related tests.
- •The subject or his/her representative voluntarily participates in the study and signs a written informed consent; and
- •The questionnaire can be completed in Chinese.
- •The patient has been informed of the trial;
排除标准
- •Histologically predominantly other types of prostate cancer, such as sarcomas, lymphomas, small cell tumors, and neuroendocrine tumors;
- •Active infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5 o F or 38.1 o C) within 1 week prior to enrollment;
- •have received systemic, ongoing immunosuppressive therapy within 14 days prior to receiving study treatment (except for adrenal replacement steroid doses not exceeding 10 mg prednisone equivalent per day in the absence of active autoimmune disease or short-term steroid therapy (<5 days) within 7 days prior to initiation of study treatment);
- •Subjects with severe cardiovascular disease;
- •New York Heart Association (NYHA) Stage III or IV congestive heart failure;
- •episode of myocardial infarction or coronary artery bypass grafting (CABG) ≤ 6 months prior to enrollment;
- •clinically significant ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or not due to dehydration;
- •history of severe non-ischemic cardiomyopathy;
- •reduced left ventricular ejection fraction (LVEF <55%), abnormal septal thickness and atrial size associated with myocardial amyloidosis, as assessed by echocardiography or multigated circuit exploration (MUGA) scan;
- •Organ function is in the following abnormalities:
- •serum aspartate aminotransferase or alanine aminotransferase > 2.5*ULN; CK > *ULN; CK-MB > *ULN; TnT > 1.5*ULN;
- •Total bilirubin > 1.5*ULN;
- •partial thromboplastin time or activated partial thromboplastin time or international normalized ratio > 1.5*ULN in the absence of anticoagulant therapy;
- •Patients who have planned or may plan to undergo extracorporeal radiation therapy or surgery for prostate cancer during the study period;
- •Prior anti-IGF-1R monotherapy and any immune checkpoint inhibitor therapy;
- •Intolerance to anti-IGF-1R monotherapy drugs and immune checkpoint inhibitors;
- •uncontrolled major active infectious disease, cardiovascular disease, pulmonary disease, hematologic disease, or psychiatric disease;
- •In the opinion of the investigator, not suitable for participation in this clinical study;
研究组 & 干预措施
Treatment with anti-IGF-1R mAb(Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)
Experimental
干预措施: anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) (Drug)
结局指标
主要结局
Safety and adverse event incidence rate
时间窗: Through primary completion of study which may take up to 6 months.
Incidence rate of adverse events graded according to the National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) version 5.0.
次要结局
- 6-month PSA progression-free survival (PSA-PFS)(6 months after first infusion)
- Overall Survival(Through primary completion of study which may take up to 6 months.)
- 3-month PSA progression-free survival (PSA-PFS)(3 months after first infusion)
- 6-month imaging progression-free survival (rPFS):(6 months after first infusion)
- PSA Response Rate(Through primary completion of study which may take up to 6 months.)
- Disease Control Rate(Through primary completion of study which may take up to 6 months.)
- Objective Response Rate(Through primary completion of study which may take up to 6 months.)
- Incidence of bone metastasis-related events (SREs)(Through primary completion of study which may take up to 6 months.)
- Quality of life (QoL)(Through primary completion of study which may take up to 6 months.)
- Quality of life (QoL) FACT-P questionnaire(Through primary completion of study which may take up to 6 months.)
- Time to pain progression(Through primary completion of study which may take up to 6 months.)
研究者
Ren Shancheng
Professor, Chief of Urology
Shanghai Changzheng Hospital
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated OphthalmopathyThyroid Associated OphthalmopathyNCT06269393Peking University People's Hospital53
已完成
1 期
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaLung Carcinoid TumorGastrin-Producing Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1Pancreatic GlucagonomaPancreatic InsulinomaRecurrent Digestive System Neuroendocrine Tumor G1Recurrent Merkel Cell CarcinomaRecurrent Pancreatic Neuroendocrine CarcinomaRegional Digestive System Neuroendocrine Tumor G1Somatostatin-Producing Neuroendocrine TumorStage III Merkel Cell CarcinomaStage IV Merkel Cell CarcinomaThyroid Gland Medullary CarcinomaParagangliomaPancreatic Polypeptide TumorNCT01204476National Cancer Institute (NCI)27
已完成
2 期
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or CirrhosisLiver FibrosisCirrhosisNCT00043303InterMune502
已完成
1 期
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03017807Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.18
已完成
1 期
A Study of IMC-TR1 in Participants With Advanced Solid TumorsNeoplasmsTumorNCT01646203Eli Lilly and Company14